Eli Lilly's other new GLP1 - Orforglipron

Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.

GLP1 reverses diabetes in human cells (in mice)

Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.

Thyroid issues with GLP1?

Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?

Are GLP1 side effects all the same?

Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.

23andMe gets into GLP1

23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.

Systematic reviews of GLP1 worth reading

Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.

Novo's new GLP1: Amycretin

Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.

GLP1's effect on ADHD

What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.

Life before GLP1s: Topiramate

Wondering what the world was doing before GLP1s? We discuss Topiramate, a popular appetite suppressant.

A new GLP1: Retatrutide

Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist

Are GLP1s primarily brain drugs?

Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?

Eli Lilly China approval and new suppliers

As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.